Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2026 07:30 ET | Source: PMGC Holdings Inc.

PMGC Holdings Inc. [NASDAQ: ELAB] Fully Utilizes All Available in $20M Equity Financing Facility, Strengthens Cash Position and Advances Multi-Sector Acquisition Strategy

PMGC Holdings Inc. [NASDAQ: ELAB] PMGC Holdings Fully Utilizes All Available in $20M Equity Financing Facility, Strengthens Cash Position and Advances Mult
April 08, 2026 07:00 ET | Source: Radiopharm Theranostics

Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial

SYDNEY, April 08, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
April 08, 2026 06:00 ET | Source: AtaiBeckley Inc.

AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs

66.7% of participants achieved an antidepressant response by Day 2 following a single intranasal dose of BPL-003 in both the 10 mg (n=6) and 12 mg (n=6) cohortsDurable responses observed at Day 85:...
April 08, 2026 06:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306...
April 08, 2026 03:00 ET | Source: Aravax

Aravax Strengthens Board with Appointments of Carsten Hellmann and Andrew Oxtoby

MELBOURNE, Australia and OXFORD, United Kingdom, April 08, 2026 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for...
April 07, 2026 16:57 ET | Source: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG). Such investors are advised to...
April 07, 2026 16:50 ET | Source: NovaBridge Biosciences

NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update

Successful transformation to global biotech platform with two mid-stage potential best-in-class/first-in-class programs, givastomig and VIS-101, with compelling proof-of-concept dataGivastomig, a...
April 07, 2026 16:05 ET | Source: Vaxcyte, Inc.

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a...
April 07, 2026 13:41 ET | Source: Neuro Salt

Neuro Salt: The TRUTH Behind the "NeuroSalt Pink Salt Trick" and Hidden Neuropathy Supplement Dangers

New York City, NY, April 07, 2026 (GLOBE NEWSWIRE) -- Neuro Salt has prompted a comprehensive independent investigation into its claims and ingredients following explosive consumer demand. With the...
April 07, 2026 10:15 ET | Source: Octane Medical Group

BioOra and Octane Biotech Sign Letter of Intent to Expand Cell Therapy Manufacturing Using the Cocoon® Platform

WELLINGTON, New Zealand and KINGSTON, Ontario, April 07, 2026 (GLOBE NEWSWIRE) -- BioOra Limited ("BioOra"), a commercial-stage cell therapy company advancing CAR-T therapies for cancer patients,...